(Reuters) - Kythera Biopharmaceuticals Inc's injection for "double chin" reduction was backed by U.S. Food and Drug Administration staff, who concluded the drug's benefits outweighed its risks.
via Reuters: Health News Read More Here..
No comments:
Post a Comment